Long-term cause-specific mortality in survivors of adolescent and young adult bone and soft tissue sarcoma: A population-based study of 28,844 patients

Cancer

Volumn 120, Issue 15, 2014, Pages 2334-2342

  Youn, Paul ^a   Milano, Michael T ^a   Constine, Louis S ^a   Travis, Lois B ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

adolescent and young adult cancer; bone and soft tissue sarcoma; mortality; Surveillance, Epidemiology, and End Results (SEER); survivorship

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVOR; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; EWING SARCOMA; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; POPULATION RESEARCH; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; YOUNG ADULT; CAUSE OF DEATH; EPIDEMIOLOGY; HEALTH SURVEY; MORTALITY; RISK FACTOR; SARCOMA; SURVIVOR; UNITED STATES;

ADOLESCENT; ADULT; CAUSE OF DEATH; FEMALE; HUMANS; MALE; POPULATION SURVEILLANCE; RISK FACTORS; SARCOMA; SEER PROGRAM; SURVIVORS; UNITED STATES; YOUNG ADULT;

EID: 84904740834     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28733     Document Type: Article

References (37)

1. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002; 20: 776-790.
2. Granowetter L, Womer R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol. 2009; 27: 2536-2541.
3. Crist WM, Anderson JR, Meza JL, et al. Intergroup Rhabdomyosarcoma Study-IV: results for patients with non-metastatic disease. J Clin Oncol. 2001; 19: 3091-3102.
4. Weitz J, Antonescu CR, Brennan MF,. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol. 2003; 21: 2719-2725.
5. Aung L, Gorlick RG, Shi W, et al. Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center experience. Cancer. 2002; 95: 1728-1734.
6. Bacci G, Ferrari C, Longhi A, et al. Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. J Pediatr Hematol Oncol. 2006; 28: 774-780.
7. Paulussen M, Ahrens S, Lehnert M, et al. Second malignancies after Ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. Ann Oncol. 2001; 12: 1619-1630.
8. Bacci G, Longhi A, Barbieri E, et al. Second malignancy in 597 patients with Ewing sarcoma of bone treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999. J Pediatr Hematol Oncol. 2005; 27: 517-520.
9. Nagarajan R, Kamruzzaman A, Ness KK, et al. Twenty years of follow-up of survivors of childhood osteosarcoma. Cancer. 2011; 117: 625-634.
10. Ginsberg JP, Goodman P, Leisenring W, et al. Long-term survivors of childhood Ewing sarcoma: report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2010; 102: 1272-1283.
11. Punyko JA, Mertens AC, Gurney JG, et al. Long-term medical effects of childhood and adolescent rhabdomyosarcoma: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2004; 44: 643-653.
12. Mansky P, Arai A, Stratton P, et al. Treatment late effects in long-term survivors of pediatric sarcoma. Pediatr Blood Cancer. 2007; 48: 192-199.
13. Guadagnolo BA, Zagars GK, Ballo MT, Strom SS, Pollock RE, Benjamin RS,. Mortality after cure of soft-tissue sarcoma treated with conservation surgery and radiotherapy. Cancer. 2008; 113: 411-418.
14. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Stat Database: Incidence-SEER 12 Regs Limited-Use, Nov. 2009 Sub (1973-2007) (Katrina/Rita Population Adjustment)-Linked To County Attributes-Total US, 1969-2007 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; 2010.
15. Sarcoma Meta-analysis Collaboration (SMAC). Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Cochrane Database Syst Rev. 2000;(4): CD001419.
16. Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001; 19: 1238-1247.
17. Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA,. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst. 2010; 102: 1584-1598.
18. Liddell FD,. Simple exact analysis of the standardized mortality ratio. J Epidemiol Community Health. 1984; 38: 85-88.
19. Novakovic B, Fears TR, Horowitz ME, Tucker MA, Wexler LH,. Late effects of therapy in survivors of Ewing's sarcoma family tumors. J Pediatr Hematol Oncol. 1997; 19: 220-225.
20. Paulino AC, Nguyen TX, Mai WY,. An analysis of primary site control and late effects according to local control modality in non-metastatic Ewing sarcoma. Pediatr Blood Cancer. 2007; 48: 423-429.
21. Eliber FC, Eliber FR, Eckardt J, et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg. 2004; 240: 686-697.
22. Eliber FC, Brennan MF, Eliber FR, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg. 2007; 246: 105-113.
23. Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol. 2003; 21: 4386-4394.
24. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: Childhood Cancer Survivor Study. J Natl Cancer Inst. 2001; 93: 618-629.
25. Henderson TO, Whitton J, Stovall M, et al. Secondary sarcomas in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2007; 99: 300-308.
26. Constine LS, Tarbell N, Hudson MM, et al. Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys. 2008; 72: 24-33.
27. Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2008; 100: 1368-1379.
28. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med. 1996; 334: 745-751.
29. van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, et al. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol. 1994; 12: 1063-1073.
30. Smith RE, Bryant J, Decillis A, Anderson S,; National Surgical Adjuvant Breast and Bowel Project Experience. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol. 2003; 21: 1195-1204.
31. Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med. 1999; 340: 351-357.
32. Travis LB, Andersson M, Gospodarowicz M, et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst. 2000; 92: 1165-1171.
33. Bhatia S, Krailo MD, Chen Z, et al. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: a report from the Children's Oncology Group. Blood. 2007; 109: 46-51.
34. Kuttesch JF Jr, Wexler LH, Marcus RB, et al. Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol. 1996; 14: 2818-2825.
35. van Dalen EC, van der Pal HJ, Kok WE, Caron HN, Kremer LC,. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer. 2006; 42: 3191-3198.
36. Sorensen K, Levitt G, Bull C, Chessells J, Sullivan I,. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. J Clin Oncol. 1997; 15: 61-68.
37. Elena JW, Travis LB, Simonds NI, et al. Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research. J Natl Cancer Inst. 2013; 105: 85-94.